{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:03:20Z","timestamp":1784333000386,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although heart failure (HF) and supraventricular tachycardias (SVT) are associated with high morbidity and mortality in pediatrics, especially, in children under 6\u00a0months; the efficacy of available treatments is limited, requiring the use of off-label therapies. The aim of the study is to investigate the efficacy, dosage, and safety of off-label ivabradine in patients under 6\u00a0months of age with HF or SVT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective observational study, which included patients under 6\u00a0months of age with HF or SVT who received ivabradine between January 2020 - May 2024. Demographic, clinical, and treatment-related variables were collected. Response variables were established according to indication, HF: heart rate (HR) and left ventricular ejection fraction (LVEF); SVT: HR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen patients (nine women) with a median age of 1.4 (1-4) months were included. Ivabradine was discontinued in five of the seven HF patients due to resolution of HF, control of HR, and improvement of LVEF. One patient discontinued ivabradine because of bradycardia. In the SVT group, four of the seven patients discontinued ivabradine after the resolution of tachyarrhythmia and improvement of HR. Two patients experienced bradycardia but did not require treatment discontinuation. HR reduction was statistically significant in both groups. In HF, the median initial ivabradine dose was 0.06\u00a0mg\/kg\/day and the maintenance dose was 0.2\u00a0mg\/kg\/day. In SVT, the initial and maintenance doses were 0.1\u00a0mg\/kg\/day and 0.24\u00a0mg\/kg\/day, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ivabradine demonstrated favorable efficacy and safety results in patients under 6\u00a0months of age with HF or SVT.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1502375","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:52:33Z","timestamp":1739861553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ivabradine in treatment of symptomatic heart failure and supraventricular tachycardias in patients under six months of age"],"prefix":"10.3389","volume":"16","author":[{"given":"L.","family":"G\u00f3mez-Ganda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Parram\u00f3n-Teixid\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giralt-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ferrer-Mendui\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Caba\u00f1as-Poy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.5863\/1551-6776-26.4.414","article-title":"Ivabradine monotherapy for the treatment of congenital junctional ectopic tachycardia in a premature neonate","volume":"26","author":"Asfour","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1540-8167.2010.01860.x","article-title":"Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine","volume":"22","author":"Bohora","year":"2011","journal-title":"J. Cardiovasc Electrophysiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jacc.2017.07.725","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","author":"Bonnet","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1017\/S1047951120001195","article-title":"Ivabradine as a stabilising anti-arrhythmic agent for multifocal atrial tachycardia","volume":"30","author":"Cohen","year":"2020","journal-title":"Cardiol. Young."},{"key":"B5","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.19102\/icrm.2023.14075","article-title":"Combination therapy of ivabradine with procainamide for the management of pediatric postoperative junctional ectopic tachycardia","volume":"14","author":"Dasgupta","year":"2023","journal-title":"J. Innov. Card. Rhythm Manag."},{"key":"B6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/apc.apc_264_20","article-title":"Ivabradine monotherapy in congenital junctional ectopic tachycardia","volume":"15","author":"Devaprasath","year":"2022","journal-title":"Ann. Pediatr. Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart rhythm."},{"key":"B8","volume-title":"Data sheet of Procoralan\u00ae (ivabradine) film-coated tablets (les laboratoires servier)","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/pace.13402","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies","volume":"41","author":"Ergul","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"B10","volume-title":"Data sheet of Corlanor\u00ae (ivabradine) film-coated tablets (Amgen Inc.)","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.carcor.2012.09.011","article-title":"Tratamiento actual de la insuficiencia cardiaca pedi\u00e1trica","volume":"48","author":"G\u00f3mez-Guzm\u00e1n","year":"2013","journal-title":"Cardiocore"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1017\/S1047951123000409","article-title":"Successful treatment of the focal ectopic atrial tachycardia in an infant with a single dose of ivabradine","volume":"33","author":"Gul","year":"2023","journal-title":"Cardiol. Young"},{"key":"B13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.hrcr.2019.03.007","article-title":"Ivabradine for treatment of tachyarrhythmias in children and young adults","volume":"5","author":"Janson","year":"2019","journal-title":"Heart Rhythm Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4103\/apc.apc_37_21","article-title":"Tachycardia-induced cardiomyopathy secondary to incessant ectopic atrial tachycardia in two infants: potential new indication for early initiation of enteral ivabradine","volume":"14","author":"Karmegaraj","year":"2021","journal-title":"Ann. Pediatr. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1053\/j.jvca.2020.02.047","article-title":"Use of ivabradine in the treatment of tachyarrhythmias after surgery for congenital heart diseases","volume":"34","author":"Khan","year":"2020","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00246-019-02149-5","article-title":"Ivabradine in post-operative junctional ectopic tachycardia (JET): breaking new ground","volume":"40","author":"Krishna","year":"2019","journal-title":"Pediatr. Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.ihj.2017.09.007","article-title":"Ivabradine for junctional ectopic tachycardia in post congenital heart surgery","volume":"69","author":"Kumar","year":"2017","journal-title":"Indian Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/2150135119876600","article-title":"Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: a preliminary study","volume":"10","author":"Kumar","year":"2019","journal-title":"World J. Pediatr. Congenit. Heart Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.anpede.2020.09.008","article-title":"Use of ivabradine in pediatric post-operative junctional ectopic tachycardia","volume":"95","author":"L\u00f3pez Fern\u00e1ndez","year":"2021","journal-title":"Pediatr (Engl Ed)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1157\/13059726","article-title":"Cardiolog\u00eda pedi\u00e1trica en la era de la gen\u00f3mica","volume":"57","author":"Mar\u00edn-Garc\u00eda","year":"2004","journal-title":"Rev. Esp. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1017\/S1047951121005187","article-title":"Congenital junctional ectopic tachycardia in the paediatric emergency department","volume":"32","author":"Memon","year":"2022","journal-title":"Cardiol. Young"},{"key":"B22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fped.2020.00313","article-title":"Ectopic atrial tachycardia in a 12-month-old girl treated with ivabradine and beta-blocker, a case report","volume":"8","author":"Michel","year":"2020","journal-title":"Front. Pediatr."},{"key":"B23","unstructured":"NIOSH list of hazardous drugs in healthcare settings, 2020\n          \n          \n          2020"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cjca.2022.10.029","article-title":"Ivabradine in the management of pediatric arrhythmias","volume":"39","author":"Penslar","year":"2023","journal-title":"Can. J. Cardiol."},{"key":"B25","first-page":"293","article-title":"Uso de la ivabradina para el tratamiento de la taquicardia ect\u00f3pica de la uni\u00f3n cong\u00e9nita","volume":"81","author":"R\u00edos","year":"2021","journal-title":"Med. (Buenos Aires)"},{"key":"B26","article-title":"Sociedad Espa\u00f1ola de Cardiolog\u00eda Pedi\u00e1trica y Cardiopat\u00edas Cong\u00e9nitas (SECPCC)","volume-title":"Cardiolog\u00eda pedi\u00e1trica y cardioapt\u00edas cong\u00e9nitas del ni\u00f1o y del adolescente. Volumen II","year":"2015"},{"key":"B27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/pace.14781","article-title":"Ivabradine in a 15-day-old male neonate with refractory focal atrial tachycardia","volume":"46","author":"Tasci","year":"2023","journal-title":"Pacing Clin. Electrophysiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.hrthm.2023.10.013","article-title":"Early experience with ivabradine for focal atrial tachycardia in pediatric patients with congenital heart disease","volume":"21","author":"Tolani","year":"2024","journal-title":"Heart rhythm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00431-023-04891-8","article-title":"Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study","volume":"182","author":"Xu","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"660855","DOI":"10.3389\/fcvm.2021.660855","article-title":"Ivabradine: a potential therapeutic for children with refractory SVT","volume":"8","author":"Younis","year":"2021","journal-title":"Front. Cardiovasc Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1502375\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T06:52:36Z","timestamp":1739861556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1502375\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":30,"alternative-id":["10.3389\/fphar.2025.1502375"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1502375","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"article-number":"1502375"}}